The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Hughes Thomas E. since 2015.
The trader's CIK number is 1611048.
At the time of the last reporting, Hughes Thomas E. was the Chief Executive Officer of Miragen Therapeutics, Inc.. (stock ticker symbol MGEN).
Also see all insider trading activities at Miragen Therapeutics, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2018 | ZFGN | 0 | $0 | 37,000 | $370,000 | 0 | $0 |
2017 | ZFGN | 0 | $0 | 0 | $0 | 93,211 | $72,052 |
2016 | ZFGN | 15,000 | $45,095 | 0 | $0 | 35,000 | $26,250 |
2015 | ZFGN | 0 | $0 | 45,626 | $1,940,670 | 38,500 | $76,474 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2018 | MGEN | 10,000 | $47,699 | 0 | $0 | 0 | $0 |
2017 | MGEN | 0 | $0 | 12,000 | $96,000 | 0 | $0 |
2. Miragen Therapeutics, Inc. (MGEN)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2018-06-28 | ZFGN | Sale | 32,000 | 10.00 | 320,000 |
2018-03-07 | ZFGN | Sale | 5,000 | 10.00 | 50,000 |
2017-05-11 | ZFGN | Option Ex | 93,211 | .77 | 72,052 |
2016-08-29 | ZFGN | Buy | 10,000 | 3.00 | 29,990 |
2016-07-22 | ZFGN | Buy | 5,000 | 3.02 | 15,105 |
2016-07-22 | ZFGN | Option Ex | 25,000 | .75 | 18,750 |
2016-01-08 | ZFGN | Option Ex | 10,000 | .75 | 7,500 |
2015-09-23 | ZFGN | Option Ex | 10,500 | .75 | 7,875 |
2015-09-17 | ZFGN | Option Ex | 4,874 | 2.45 | 11,941 |
2015-09-18 | ZFGN | Option Ex | 23,126 | 2.45 | 56,658 |
2015-09-17 | ZFGN | Sale | 22,500 | 40.00 | 900,000 |
2015-09-18 | ZFGN | Sale | 23,126 | 45.00 | 1,040,670 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2018-10-11 | MGEN | Buy | 10,000 | 4.77 | 47,699 |
2017-12-20 | MGEN | Sale | 12,000 | 8.00 | 96,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hughes Thomas E. (Chief Executive Officer of Miragen Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.